-
1
-
-
84858255142
-
Molecular mechanisms of HIV entry
-
10.1007/978-1-4614-0980-9_10, 22297516
-
Wilen CB, Tilton JC, Doms RW. Molecular mechanisms of HIV entry. Adv Exp Med Biol 2012, 726:223-242. 10.1007/978-1-4614-0980-9_10, 22297516.
-
(2012)
Adv Exp Med Biol
, vol.726
, pp. 223-242
-
-
Wilen, C.B.1
Tilton, J.C.2
Doms, R.W.3
-
2
-
-
79952699891
-
Coreceptors and HIV-1 pathogenesis
-
10.1007/s11904-010-0069-x, 21188555
-
Gorry PR, Ancuta P. Coreceptors and HIV-1 pathogenesis. Curr HIV/AIDS Rep 2011, 8(1):45-53. 10.1007/s11904-010-0069-x, 21188555.
-
(2011)
Curr HIV/AIDS Rep
, vol.8
, Issue.1
, pp. 45-53
-
-
Gorry, P.R.1
Ancuta, P.2
-
3
-
-
0036333648
-
The crown and stem of the V3 loop play distinct roles in human immunodeficiency virus type 1 envelope glycoprotein interactions with the CCR5 coreceptor
-
10.1128/JVI.76.17.8953-8957.2002, 136967, 12163614
-
Cormier EG, Dragic T. The crown and stem of the V3 loop play distinct roles in human immunodeficiency virus type 1 envelope glycoprotein interactions with the CCR5 coreceptor. J Virol 2002, 76(17):8953-8957. 10.1128/JVI.76.17.8953-8957.2002, 136967, 12163614.
-
(2002)
J Virol
, vol.76
, Issue.17
, pp. 8953-8957
-
-
Cormier, E.G.1
Dragic, T.2
-
4
-
-
27744597054
-
Structure of a V3-containing HIV-1 gp120 core
-
10.1126/science.1118398, 2408531, 16284180
-
Huang CC, Tang M, Zhang MY, Majeed S, Montabana E, Stanfield RL, Dimitrov DS, Korber B, Sodroski J, Wilson IA. Structure of a V3-containing HIV-1 gp120 core. Science 2005, 310(5750):1025-1028. 10.1126/science.1118398, 2408531, 16284180.
-
(2005)
Science
, vol.310
, Issue.5750
, pp. 1025-1028
-
-
Huang, C.C.1
Tang, M.2
Zhang, M.Y.3
Majeed, S.4
Montabana, E.5
Stanfield, R.L.6
Dimitrov, D.S.7
Korber, B.8
Sodroski, J.9
Wilson, I.A.10
-
5
-
-
0033525590
-
Tyrosine sulfation of the amino terminus of CCR5 facilitates HIV-1 entry
-
10.1016/S0092-8674(00)80577-2, 10089882
-
Farzan M, Mirzabekov T, Kolchinsky P, Wyatt R, Cayabyab M, Gerard NP, Gerard C, Sodroski J, Choe H. Tyrosine sulfation of the amino terminus of CCR5 facilitates HIV-1 entry. Cell 1999, 96(5):667-676. 10.1016/S0092-8674(00)80577-2, 10089882.
-
(1999)
Cell
, vol.96
, Issue.5
, pp. 667-676
-
-
Farzan, M.1
Mirzabekov, T.2
Kolchinsky, P.3
Wyatt, R.4
Cayabyab, M.5
Gerard, N.P.6
Gerard, C.7
Sodroski, J.8
Choe, H.9
-
6
-
-
0033050176
-
Effect of mutations in the second extracellular loop of CXCR4 on its utilization by human and feline immunodeficiency viruses
-
104012, 10074102
-
Brelot A, Heveker N, Adema K, Hosie MJ, Willett B, Alizon M. Effect of mutations in the second extracellular loop of CXCR4 on its utilization by human and feline immunodeficiency viruses. J Virol 1999, 73(4):2576-2586. 104012, 10074102.
-
(1999)
J Virol
, vol.73
, Issue.4
, pp. 2576-2586
-
-
Brelot, A.1
Heveker, N.2
Adema, K.3
Hosie, M.J.4
Willett, B.5
Alizon, M.6
-
7
-
-
0031883554
-
A tyrosine-rich region in the N terminus of CCR5 is important for human immunodeficiency virus type 1 entry and mediates an association between gp120 and CCR5
-
124591, 9445013
-
Farzan M, Choe H, Vaca L, Martin K, Sun Y, Desjardins E, Ruffing N, Wu L, Wyatt R, Gerard N. A tyrosine-rich region in the N terminus of CCR5 is important for human immunodeficiency virus type 1 entry and mediates an association between gp120 and CCR5. J Virol 1998, 72(2):1160-1164. 124591, 9445013.
-
(1998)
J Virol
, vol.72
, Issue.2
, pp. 1160-1164
-
-
Farzan, M.1
Choe, H.2
Vaca, L.3
Martin, K.4
Sun, Y.5
Desjardins, E.6
Ruffing, N.7
Wu, L.8
Wyatt, R.9
Gerard, N.10
-
8
-
-
0034705106
-
Specific interaction of CCR5 amino-terminal domain peptides containing sulfotyrosines with HIV-1 envelope glycoprotein gp120
-
10.1073/pnas.97.11.5762, 18507, 10823934
-
Cormier EG, Persuh M, Thompson DA, Lin SW, Sakmar TP, Olson WC, Dragic T. Specific interaction of CCR5 amino-terminal domain peptides containing sulfotyrosines with HIV-1 envelope glycoprotein gp120. Proc Natl Acad Sci USA 2000, 97(11):5762-5767. 10.1073/pnas.97.11.5762, 18507, 10823934.
-
(2000)
Proc Natl Acad Sci USA
, vol.97
, Issue.11
, pp. 5762-5767
-
-
Cormier, E.G.1
Persuh, M.2
Thompson, D.A.3
Lin, S.W.4
Sakmar, T.P.5
Olson, W.C.6
Dragic, T.7
-
9
-
-
40849098660
-
Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists
-
Kondru R, Zhang J, Ji C, Mirzadegan T, Rotstein D, Sankuratri S, Dioszegi M. Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists. Mol Pharmacol 2008, 73(3):789-800.
-
(2008)
Mol Pharmacol
, vol.73
, Issue.3
, pp. 789-800
-
-
Kondru, R.1
Zhang, J.2
Ji, C.3
Mirzadegan, T.4
Rotstein, D.5
Sankuratri, S.6
Dioszegi, M.7
-
10
-
-
0034625144
-
A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5
-
10.1073/pnas.090576697, 25881, 10779565
-
Dragic T, Trkola A, Thompson DA, Cormier EG, Kajumo FA, Maxwell E, Lin SW, Ying W, Smith SO, Sakmar TP. A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Proc Natl Acad Sci USA 2000, 97(10):5639-5644. 10.1073/pnas.090576697, 25881, 10779565.
-
(2000)
Proc Natl Acad Sci USA
, vol.97
, Issue.10
, pp. 5639-5644
-
-
Dragic, T.1
Trkola, A.2
Thompson, D.A.3
Cormier, E.G.4
Kajumo, F.A.5
Maxwell, E.6
Lin, S.W.7
Ying, W.8
Smith, S.O.9
Sakmar, T.P.10
-
11
-
-
33744954776
-
Structural and molecular interactions of CCR5 inhibitors with CCR5
-
10.1074/jbc.M512688200, 16476734
-
Maeda K, Das D, Ogata-Aoki H, Nakata H, Miyakawa T, Tojo Y, Norman R, Takaoka Y, Ding J, Arnold GF. Structural and molecular interactions of CCR5 inhibitors with CCR5. J Biol Chem 2006, 281(18):12688-12698. 10.1074/jbc.M512688200, 16476734.
-
(2006)
J Biol Chem
, vol.281
, Issue.18
, pp. 12688-12698
-
-
Maeda, K.1
Das, D.2
Ogata-Aoki, H.3
Nakata, H.4
Miyakawa, T.5
Tojo, Y.6
Norman, R.7
Takaoka, Y.8
Ding, J.9
Arnold, G.F.10
-
12
-
-
33646514864
-
Interaction of small molecule inhibitors of HIV-1 entry with CCR5
-
10.1016/j.virol.2006.01.018, 16494916
-
Seibert C, Ying W, Gavrilov S, Tsamis F, Kuhmann SE, Palani A, Tagat JR, Clader JW, McCombie SW, Baroudy BM. Interaction of small molecule inhibitors of HIV-1 entry with CCR5. Virology 2006, 349(1):41-54. 10.1016/j.virol.2006.01.018, 16494916.
-
(2006)
Virology
, vol.349
, Issue.1
, pp. 41-54
-
-
Seibert, C.1
Ying, W.2
Gavrilov, S.3
Tsamis, F.4
Kuhmann, S.E.5
Palani, A.6
Tagat, J.R.7
Clader, J.W.8
McCombie, S.W.9
Baroudy, B.M.10
-
13
-
-
0037404511
-
Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry
-
10.1128/JVI.77.9.5201-5208.2003, 153966, 12692222
-
Tsamis F, Gavrilov S, Kajumo F, Seibert C, Kuhmann S, Ketas T, Trkola A, Palani A, Clader JW, Tagat JR. Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry. J Virol 2003, 77(9):5201-5208. 10.1128/JVI.77.9.5201-5208.2003, 153966, 12692222.
-
(2003)
J Virol
, vol.77
, Issue.9
, pp. 5201-5208
-
-
Tsamis, F.1
Gavrilov, S.2
Kajumo, F.3
Seibert, C.4
Kuhmann, S.5
Ketas, T.6
Trkola, A.7
Palani, A.8
Clader, J.W.9
Tagat, J.R.10
-
14
-
-
15744391870
-
The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor
-
10.1124/mol.104.008565, 15644495
-
Watson C, Jenkinson S, Kazmierski W, Kenakin T. The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor. Mol Pharmacol 2005, 67(4):1268-1282. 10.1124/mol.104.008565, 15644495.
-
(2005)
Mol Pharmacol
, vol.67
, Issue.4
, pp. 1268-1282
-
-
Watson, C.1
Jenkinson, S.2
Kazmierski, W.3
Kenakin, T.4
-
15
-
-
77957204794
-
A maraviroc-resistant HIV-1 with narrow cross-resistance to other CCR5 antagonists depends on both N-terminal and extracellular loop domains of drug-bound CCR5
-
10.1128/JVI.01109-10, 2950574, 20702642
-
Tilton JC, Wilen CB, Didigu CA, Sinha R, Harrison JE, Agrawal-Gamse C, Henning EA, Bushman FD, Martin JN, Deeks SG. A maraviroc-resistant HIV-1 with narrow cross-resistance to other CCR5 antagonists depends on both N-terminal and extracellular loop domains of drug-bound CCR5. J Virol 2010, 84:10863-10876. 10.1128/JVI.01109-10, 2950574, 20702642.
-
(2010)
J Virol
, vol.84
, pp. 10863-10876
-
-
Tilton, J.C.1
Wilen, C.B.2
Didigu, C.A.3
Sinha, R.4
Harrison, J.E.5
Agrawal-Gamse, C.6
Henning, E.A.7
Bushman, F.D.8
Martin, J.N.9
Deeks, S.G.10
-
16
-
-
27644510382
-
Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity
-
10.1128/AAC.49.11.4721-4732.2005, 1280117, 16251317
-
Dorr P, Westby M, Dobbs S, Griffin P, Irvine B, Macartney M, Mori J, Rickett G, Smith-Burchnell C, Napier C. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 2005, 49(11):4721-4732. 10.1128/AAC.49.11.4721-4732.2005, 1280117, 16251317.
-
(2005)
Antimicrob Agents Chemother
, vol.49
, Issue.11
, pp. 4721-4732
-
-
Dorr, P.1
Westby, M.2
Dobbs, S.3
Griffin, P.4
Irvine, B.5
Macartney, M.6
Mori, J.7
Rickett, G.8
Smith-Burchnell, C.9
Napier, C.10
-
17
-
-
27744548649
-
The discovery of the CCR5 receptor antagonist, UK-427,857, a new agent for the treatment of HIV infection and AIDS
-
Wood A, Armour D. The discovery of the CCR5 receptor antagonist, UK-427,857, a new agent for the treatment of HIV infection and AIDS. Prog Med Chem 2005, 43:239-271.
-
(2005)
Prog Med Chem
, vol.43
, pp. 239-271
-
-
Wood, A.1
Armour, D.2
-
18
-
-
79955438412
-
Maraviroc
-
London: Hodder & Stoughton Ltd, Grayson L, Crowe S, McCarthy J, Mills J, Mouton J, Norrby SR, Paterson D, Pfaller M, 6
-
Gorry PR, Ellett A, Lewin SR. Maraviroc. Kucers' The Use of Antibiotics 2010, 2869-2876. London: Hodder & Stoughton Ltd, Grayson L, Crowe S, McCarthy J, Mills J, Mouton J, Norrby SR, Paterson D, Pfaller M, 6.
-
(2010)
Kucers' The Use of Antibiotics
, pp. 2869-2876
-
-
Gorry, P.R.1
Ellett, A.2
Lewin, S.R.3
-
19
-
-
28944454412
-
Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1
-
10.1128/AAC.49.12.4911-4919.2005, 1315929, 16304152
-
Strizki JM, Tremblay C, Xu S, Wojcik L, Wagner N, Gonsiorek W, Hipkin RW, Chou CC, Pugliese-Sivo C, Xiao Y. Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1. Antimicrob Agents Chemother 2005, 49(12):4911-4919. 10.1128/AAC.49.12.4911-4919.2005, 1315929, 16304152.
-
(2005)
Antimicrob Agents Chemother
, vol.49
, Issue.12
, pp. 4911-4919
-
-
Strizki, J.M.1
Tremblay, C.2
Xu, S.3
Wojcik, L.4
Wagner, N.5
Gonsiorek, W.6
Hipkin, R.W.7
Chou, C.C.8
Pugliese-Sivo, C.9
Xiao, Y.10
-
20
-
-
3543144738
-
Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro
-
10.1128/JVI.78.16.8654-8662.2004, 479103, 15280474
-
Maeda K, Nakata H, Koh Y, Miyakawa T, Ogata H, Takaoka Y, Shibayama S, Sagawa K, Fukushima D, Moravek J. Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro. J Virol 2004, 78(16):8654-8662. 10.1128/JVI.78.16.8654-8662.2004, 479103, 15280474.
-
(2004)
J Virol
, vol.78
, Issue.16
, pp. 8654-8662
-
-
Maeda, K.1
Nakata, H.2
Koh, Y.3
Miyakawa, T.4
Ogata, H.5
Takaoka, Y.6
Shibayama, S.7
Sagawa, K.8
Fukushima, D.9
Moravek, J.10
-
21
-
-
13044256383
-
A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity
-
10.1073/pnas.96.10.5698, 21923, 10318947
-
Baba M, Nishimura O, Kanzaki N, Okamoto M, Sawada H, Iizawa Y, Shiraishi M, Aramaki Y, Okonogi K, Ogawa Y. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc Natl Acad Sci USA 1999, 96(10):5698-5703. 10.1073/pnas.96.10.5698, 21923, 10318947.
-
(1999)
Proc Natl Acad Sci USA
, vol.96
, Issue.10
, pp. 5698-5703
-
-
Baba, M.1
Nishimura, O.2
Kanzaki, N.3
Okamoto, M.4
Sawada, H.5
Iizawa, Y.6
Shiraishi, M.7
Aramaki, Y.8
Okonogi, K.9
Ogawa, Y.10
-
22
-
-
33646443202
-
Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir
-
10.1128/JVI.80.10.4909-4920.2006, 1472081, 16641282
-
Westby M, Lewis M, Whitcomb J, Youle M, Pozniak AL, James IT, Jenkins TM, Perros M, van der Ryst E. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J Virol 2006, 80(10):4909-4920. 10.1128/JVI.80.10.4909-4920.2006, 1472081, 16641282.
-
(2006)
J Virol
, vol.80
, Issue.10
, pp. 4909-4920
-
-
Westby, M.1
Lewis, M.2
Whitcomb, J.3
Youle, M.4
Pozniak, A.L.5
James, I.T.6
Jenkins, T.M.7
Perros, M.8
van der Ryst, E.9
-
23
-
-
66249094578
-
Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo
-
10.1371/journal.pone.0005683, 2682648, 19479085
-
Tsibris AM, Korber B, Arnaout R, Russ C, Lo CC, Leitner T, Gaschen B, Theiler J, Paredes R, Su Z. Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo. PLoS One 2009, 4(5):e5683. 10.1371/journal.pone.0005683, 2682648, 19479085.
-
(2009)
PLoS One
, vol.4
, Issue.5
-
-
Tsibris, A.M.1
Korber, B.2
Arnaout, R.3
Russ, C.4
Lo, C.C.5
Leitner, T.6
Gaschen, B.7
Theiler, J.8
Paredes, R.9
Su, Z.10
-
24
-
-
54849145400
-
Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection
-
10.1056/NEJMoa0803154, 18832245
-
Fatkenheuer G, Nelson M, Lazzarin A, Konourina I, Hoepelman AI, Lampiris H, Hirschel B, Tebas P, Raffi F, Trottier B. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med 2008, 359(14):1442-1455. 10.1056/NEJMoa0803154, 18832245.
-
(2008)
N Engl J Med
, vol.359
, Issue.14
, pp. 1442-1455
-
-
Fatkenheuer, G.1
Nelson, M.2
Lazzarin, A.3
Konourina, I.4
Hoepelman, A.I.5
Lampiris, H.6
Hirschel, B.7
Tebas, P.8
Raffi, F.9
Trottier, B.10
-
25
-
-
77749271329
-
Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection
-
10.1086/650697, 20151839
-
Cooper DA, Heera J, Goodrich J, Tawadrous M, Saag M, Dejesus E, Clumeck N, Walmsley S, Ting N, Coakley E. Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. J Infect Dis 2010, 201(6):803-813. 10.1086/650697, 20151839.
-
(2010)
J Infect Dis
, vol.201
, Issue.6
, pp. 803-813
-
-
Cooper, D.A.1
Heera, J.2
Goodrich, J.3
Tawadrous, M.4
Saag, M.5
Dejesus, E.6
Clumeck, N.7
Walmsley, S.8
Ting, N.9
Coakley, E.10
-
26
-
-
34347379935
-
Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211
-
10.1086/518797, 17570119
-
Gulick RM, Su Z, Flexner C, Hughes MD, Skolnik PR, Wilkin TJ, Gross R, Krambrink A, Coakley E, Greaves WL. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211. J Infect Dis 2007, 196(2):304-312. 10.1086/518797, 17570119.
-
(2007)
J Infect Dis
, vol.196
, Issue.2
, pp. 304-312
-
-
Gulick, R.M.1
Su, Z.2
Flexner, C.3
Hughes, M.D.4
Skolnik, P.R.5
Wilkin, T.J.6
Gross, R.7
Krambrink, A.8
Coakley, E.9
Greaves, W.L.10
-
27
-
-
54749134143
-
Phase II study of vicriviroc versus efavirenz (both with zidovudine/lamivudine) in treatment-naive subjects with HIV-1 infection
-
10.1086/592052, 18783318
-
Landovitz RJ, Angel JB, Hoffmann C, Horst H, Opravil M, Long J, Greaves W, Fatkenheuer G. Phase II study of vicriviroc versus efavirenz (both with zidovudine/lamivudine) in treatment-naive subjects with HIV-1 infection. J Infect Dis 2008, 198(8):1113-1122. 10.1086/592052, 18783318.
-
(2008)
J Infect Dis
, vol.198
, Issue.8
, pp. 1113-1122
-
-
Landovitz, R.J.1
Angel, J.B.2
Hoffmann, C.3
Horst, H.4
Opravil, M.5
Long, J.6
Greaves, W.7
Fatkenheuer, G.8
-
28
-
-
62949113396
-
Virologic failure in therapy-naive subjects on aplaviroc plus lopinavir-ritonavir: detection of aplaviroc resistance requires clonal analysis of envelope
-
10.1128/AAC.01057-08, 2650553, 19075068
-
Kitrinos KM, Amrine-Madsen H, Irlbeck DM, Word JM, Demarest JF. Virologic failure in therapy-naive subjects on aplaviroc plus lopinavir-ritonavir: detection of aplaviroc resistance requires clonal analysis of envelope. Antimicrob Agents Chemother 2009, 53(3):1124-1131. 10.1128/AAC.01057-08, 2650553, 19075068.
-
(2009)
Antimicrob Agents Chemother
, vol.53
, Issue.3
, pp. 1124-1131
-
-
Kitrinos, K.M.1
Amrine-Madsen, H.2
Irlbeck, D.M.3
Word, J.M.4
Demarest, J.F.5
-
29
-
-
62949107184
-
Virologic failure in first-line human immunodeficiency virus therapy with a CCR5 entry inhibitor, aplaviroc, plus a fixed-dose combination of lamivudine-zidovudine: nucleoside reverse transcriptase inhibitor resistance regardless of envelope tropism
-
10.1128/AAC.01055-08, 2650552, 19075055
-
Demarest JF, Amrine-Madsen H, Irlbeck DM, Kitrinos KM. Virologic failure in first-line human immunodeficiency virus therapy with a CCR5 entry inhibitor, aplaviroc, plus a fixed-dose combination of lamivudine-zidovudine: nucleoside reverse transcriptase inhibitor resistance regardless of envelope tropism. Antimicrob Agents Chemother 2009, 53(3):1116-1123. 10.1128/AAC.01055-08, 2650552, 19075055.
-
(2009)
Antimicrob Agents Chemother
, vol.53
, Issue.3
, pp. 1116-1123
-
-
Demarest, J.F.1
Amrine-Madsen, H.2
Irlbeck, D.M.3
Kitrinos, K.M.4
-
30
-
-
84863116880
-
HIV-1 clinical isolates resistant to CCR5 antagonists exhibit delayed entry kinetics that are corrected in the presence of drug
-
10.1128/JVI.06421-11, 3255837, 22090117
-
Putcharoen O, Lee SH, Henrich TJ, Hu Z, Vanichanan J, Coakley E, Greaves W, Gulick RM, Kuritzkes DR, Tsibris AM. HIV-1 clinical isolates resistant to CCR5 antagonists exhibit delayed entry kinetics that are corrected in the presence of drug. J Virol 2012, 86(2):1119-1128. 10.1128/JVI.06421-11, 3255837, 22090117.
-
(2012)
J Virol
, vol.86
, Issue.2
, pp. 1119-1128
-
-
Putcharoen, O.1
Lee, S.H.2
Henrich, T.J.3
Hu, Z.4
Vanichanan, J.5
Coakley, E.6
Greaves, W.7
Gulick, R.M.8
Kuritzkes, D.R.9
Tsibris, A.M.10
-
31
-
-
77951884647
-
Characterization of emergent HIV resistance in treatment-naive subjects enrolled in a vicriviroc phase 2 trial
-
10.1086/652189, 20373959
-
McNicholas P, Wei Y, Whitcomb J, Greaves W, Black TA, Tremblay CL, Strizki JM. Characterization of emergent HIV resistance in treatment-naive subjects enrolled in a vicriviroc phase 2 trial. J Infect Dis 2010, 201(10):1470-1480. 10.1086/652189, 20373959.
-
(2010)
J Infect Dis
, vol.201
, Issue.10
, pp. 1470-1480
-
-
McNicholas, P.1
Wei, Y.2
Whitcomb, J.3
Greaves, W.4
Black, T.A.5
Tremblay, C.L.6
Strizki, J.M.7
-
32
-
-
77649188640
-
Clinical resistance to vicriviroc through adaptive V3 loop mutations in HIV-1 subtype D gp120 that alter interactions with the N-terminus and ECL2 of CCR5
-
10.1016/j.virol.2010.01.037, 20172579
-
Ogert RA, Hou Y, Ba L, Wojcik L, Qiu P, Murgolo N, Duca J, Dunkle LM, Ralston R, Howe JA. Clinical resistance to vicriviroc through adaptive V3 loop mutations in HIV-1 subtype D gp120 that alter interactions with the N-terminus and ECL2 of CCR5. Virology 2010, 400(1):145-155. 10.1016/j.virol.2010.01.037, 20172579.
-
(2010)
Virology
, vol.400
, Issue.1
, pp. 145-155
-
-
Ogert, R.A.1
Hou, Y.2
Ba, L.3
Wojcik, L.4
Qiu, P.5
Murgolo, N.6
Duca, J.7
Dunkle, L.M.8
Ralston, R.9
Howe, J.A.10
-
33
-
-
49149118151
-
In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject
-
10.1128/JVI.00444-08, 2519584, 18495779
-
Tsibris AM, Sagar M, Gulick RM, Su Z, Hughes M, Greaves W, Subramanian M, Flexner C, Giguel F, Leopold KE. In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject. J Virol 2008, 82(16):8210-8214. 10.1128/JVI.00444-08, 2519584, 18495779.
-
(2008)
J Virol
, vol.82
, Issue.16
, pp. 8210-8214
-
-
Tsibris, A.M.1
Sagar, M.2
Gulick, R.M.3
Su, Z.4
Hughes, M.5
Greaves, W.6
Subramanian, M.7
Flexner, C.8
Giguel, F.9
Leopold, K.E.10
-
34
-
-
33847237614
-
Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry
-
10.1128/JVI.02006-06, 1865946, 17182681
-
Westby M, Smith-Burchnell C, Mori J, Lewis M, Mosley M, Stockdale M, Dorr P, Ciaramella G, Perros M. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J Virol 2007, 81(5):2359-2371. 10.1128/JVI.02006-06, 1865946, 17182681.
-
(2007)
J Virol
, vol.81
, Issue.5
, pp. 2359-2371
-
-
Westby, M.1
Smith-Burchnell, C.2
Mori, J.3
Lewis, M.4
Mosley, M.5
Stockdale, M.6
Dorr, P.7
Ciaramella, G.8
Perros, M.9
-
35
-
-
34047271098
-
HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry
-
10.1016/j.virol.2006.11.004, 1892195, 17166540
-
Pugach P, Marozsan AJ, Ketas TJ, Landes EL, Moore JP, Kuhmann SE. HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry. Virology 2007, 361(1):212-228. 10.1016/j.virol.2006.11.004, 1892195, 17166540.
-
(2007)
Virology
, vol.361
, Issue.1
, pp. 212-228
-
-
Pugach, P.1
Marozsan, A.J.2
Ketas, T.J.3
Landes, E.L.4
Moore, J.P.5
Kuhmann, S.E.6
-
36
-
-
64849083122
-
Inefficient entry of vicriviroc-resistant HIV-1 via the inhibitor-CCR5 complex at low cell surface CCR5 densities
-
10.1016/j.virol.2009.02.044, 2674391, 19303620
-
Pugach P, Ray N, Klasse PJ, Ketas TJ, Michael E, Doms RW, Lee B, Moore JP. Inefficient entry of vicriviroc-resistant HIV-1 via the inhibitor-CCR5 complex at low cell surface CCR5 densities. Virology 2009, 387(2):296-302. 10.1016/j.virol.2009.02.044, 2674391, 19303620.
-
(2009)
Virology
, vol.387
, Issue.2
, pp. 296-302
-
-
Pugach, P.1
Ray, N.2
Klasse, P.J.3
Ketas, T.J.4
Michael, E.5
Doms, R.W.6
Lee, B.7
Moore, J.P.8
-
37
-
-
40849085150
-
Mapping resistance to the CCR5 co-receptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp120
-
10.1016/j.virol.2007.12.009, 18190945
-
Ogert RA, Wojcik L, Buontempo C, Ba L, Buontempo P, Ralston R, Strizki J, Howe JA. Mapping resistance to the CCR5 co-receptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp120. Virology 2008, 373(2):387-399. 10.1016/j.virol.2007.12.009, 18190945.
-
(2008)
Virology
, vol.373
, Issue.2
, pp. 387-399
-
-
Ogert, R.A.1
Wojcik, L.2
Buontempo, C.3
Ba, L.4
Buontempo, P.5
Ralston, R.6
Strizki, J.7
Howe, J.A.8
-
38
-
-
84863363083
-
Differential use of CCR5 by HIV-1 clinical isolates resistant to small-molecule CCR5 antagonists
-
10.1128/AAC.06061-11, 3318367, 22252820
-
Henrich TJ, Lewine NR, Lee SH, Rao SS, Berro R, Gulick RM, Moore JP, Tsibris AM, Kuritzkes DR. Differential use of CCR5 by HIV-1 clinical isolates resistant to small-molecule CCR5 antagonists. Antimicrob Agents Chemother 2012, 56(4):1931-1935. 10.1128/AAC.06061-11, 3318367, 22252820.
-
(2012)
Antimicrob Agents Chemother
, vol.56
, Issue.4
, pp. 1931-1935
-
-
Henrich, T.J.1
Lewine, N.R.2
Lee, S.H.3
Rao, S.S.4
Berro, R.5
Gulick, R.M.6
Moore, J.P.7
Tsibris, A.M.8
Kuritzkes, D.R.9
-
39
-
-
76449113232
-
HIV type 1 from a patient with baseline resistance to CCR5 antagonists uses drug-bound receptor for entry
-
10.1089/aid.2009.0132, 2858898, 20055594
-
Tilton JC, Amrine-Madsen H, Miamidian JL, Kitrinos KM, Pfaff J, Demarest JF, Ray N, Jeffrey JL, Labranche CC, Doms RW. HIV type 1 from a patient with baseline resistance to CCR5 antagonists uses drug-bound receptor for entry. AIDS Res Hum Retroviruses 2010, 26(1):13-24. 10.1089/aid.2009.0132, 2858898, 20055594.
-
(2010)
AIDS Res Hum Retroviruses
, vol.26
, Issue.1
, pp. 13-24
-
-
Tilton, J.C.1
Amrine-Madsen, H.2
Miamidian, J.L.3
Kitrinos, K.M.4
Pfaff, J.5
Demarest, J.F.6
Ray, N.7
Jeffrey, J.L.8
Labranche, C.C.9
Doms, R.W.10
-
40
-
-
12144289333
-
Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor
-
10.1128/JVI.78.6.2790-2807.2004, 353740, 14990699
-
Kuhmann SE, Pugach P, Kunstman KJ, Taylor J, Stanfield RL, Snyder A, Strizki JM, Riley J, Baroudy BM, Wilson IA. Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor. J Virol 2004, 78(6):2790-2807. 10.1128/JVI.78.6.2790-2807.2004, 353740, 14990699.
-
(2004)
J Virol
, vol.78
, Issue.6
, pp. 2790-2807
-
-
Kuhmann, S.E.1
Pugach, P.2
Kunstman, K.J.3
Taylor, J.4
Stanfield, R.L.5
Snyder, A.6
Strizki, J.M.7
Riley, J.8
Baroudy, B.M.9
Wilson, I.A.10
-
41
-
-
78650236401
-
Evolution of CCR5 antagonist resistance in an HIV-1 subtype C clinical isolate
-
10.1097/QAI.0b013e3181f25574, 3070184, 20856130
-
Henrich TJ, Tsibris AM, Lewine NR, Konstantinidis I, Leopold KE, Sagar M, Kuritzkes DR. Evolution of CCR5 antagonist resistance in an HIV-1 subtype C clinical isolate. J Acquir Immune Defic Syndr 2010, 55(4):420-427. 10.1097/QAI.0b013e3181f25574, 3070184, 20856130.
-
(2010)
J Acquir Immune Defic Syndr
, vol.55
, Issue.4
, pp. 420-427
-
-
Henrich, T.J.1
Tsibris, A.M.2
Lewine, N.R.3
Konstantinidis, I.4
Leopold, K.E.5
Sagar, M.6
Kuritzkes, D.R.7
-
42
-
-
77953305009
-
HIV-1 resistance to CCR5 antagonists associated with highly efficient use of CCR5 and altered tropism on primary CD4+ T cells
-
10.1128/JVI.00374-10, 2903254, 20410277
-
Pfaff JM, Wilen CB, Harrison JE, Demarest JF, Lee B, Doms RW, Tilton JC. HIV-1 resistance to CCR5 antagonists associated with highly efficient use of CCR5 and altered tropism on primary CD4+ T cells. J Virol 2010, 84(13):6505-6514. 10.1128/JVI.00374-10, 2903254, 20410277.
-
(2010)
J Virol
, vol.84
, Issue.13
, pp. 6505-6514
-
-
Pfaff, J.M.1
Wilen, C.B.2
Harrison, J.E.3
Demarest, J.F.4
Lee, B.5
Doms, R.W.6
Tilton, J.C.7
-
43
-
-
79953086675
-
Resistance of a human immunodeficiency virus type 1 isolate to a small molecule CCR5 inhibitor can involve sequence changes in both gp120 and gp41
-
10.1016/j.virol.2010.12.052, 3070043, 21356539
-
Anastassopoulou CG, Ketas TJ, Depetris RS, Thomas AM, Klasse PJ, Moore JP. Resistance of a human immunodeficiency virus type 1 isolate to a small molecule CCR5 inhibitor can involve sequence changes in both gp120 and gp41. Virology 2011, 413(1):47-59. 10.1016/j.virol.2010.12.052, 3070043, 21356539.
-
(2011)
Virology
, vol.413
, Issue.1
, pp. 47-59
-
-
Anastassopoulou, C.G.1
Ketas, T.J.2
Depetris, R.S.3
Thomas, A.M.4
Klasse, P.J.5
Moore, J.P.6
-
44
-
-
65249151382
-
Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41
-
10.1073/pnas.0811713106, 2664029, 19289833
-
Anastassopoulou CG, Ketas TJ, Klasse PJ, Moore JP. Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41. Proc Natl Acad Sci USA 2009, 106(13):5318-5323. 10.1073/pnas.0811713106, 2664029, 19289833.
-
(2009)
Proc Natl Acad Sci USA
, vol.106
, Issue.13
, pp. 5318-5323
-
-
Anastassopoulou, C.G.1
Ketas, T.J.2
Klasse, P.J.3
Moore, J.P.4
-
45
-
-
84860837386
-
Effects of sequence changes in the HIV-1 gp41 fusion peptide on CCR5 inhibitor resistance
-
10.1016/j.virol.2012.03.008, 22520838
-
Anastassopoulou CG, Ketas TJ, Sanders RW, Klasse PJ, Moore JP. Effects of sequence changes in the HIV-1 gp41 fusion peptide on CCR5 inhibitor resistance. Virology 2012, 428(2):86-97. 10.1016/j.virol.2012.03.008, 22520838.
-
(2012)
Virology
, vol.428
, Issue.2
, pp. 86-97
-
-
Anastassopoulou, C.G.1
Ketas, T.J.2
Sanders, R.W.3
Klasse, P.J.4
Moore, J.P.5
-
46
-
-
79951810774
-
Mapping and characterization of vicriviroc resistance mutations from HIV-1 isolated from treatment-experienced subjects enrolled in a phase II study (VICTOR-E1)
-
10.1097/QAI.0b013e3181ff63ee, 21209592
-
McNicholas PM, Mann PA, Wojcik L, Phd PQ, Lee E, McCarthy M, Shen J, Black TA, Strizki JM. Mapping and characterization of vicriviroc resistance mutations from HIV-1 isolated from treatment-experienced subjects enrolled in a phase II study (VICTOR-E1). J Acquir Immune Defic Syndr 2011, 56(3):222-229. 10.1097/QAI.0b013e3181ff63ee, 21209592.
-
(2011)
J Acquir Immune Defic Syndr
, vol.56
, Issue.3
, pp. 222-229
-
-
McNicholas, P.M.1
Mann, P.A.2
Wojcik, L.3
Phd, P.Q.4
Lee, E.5
McCarthy, M.6
Shen, J.7
Black, T.A.8
Strizki, J.M.9
-
48
-
-
70049098271
-
Two HIV-1 variants resistant to small molecule CCR5 inhibitors differ in how they use CCR5 for entry
-
10.1371/journal.ppat.1000548, 2718843, 19680536
-
Berro R, Sanders RW, Lu M, Klasse PJ, Moore JP. Two HIV-1 variants resistant to small molecule CCR5 inhibitors differ in how they use CCR5 for entry. PLoS Pathog 2009, 5(8):e1000548. 10.1371/journal.ppat.1000548, 2718843, 19680536.
-
(2009)
PLoS Pathog
, vol.5
, Issue.8
-
-
Berro, R.1
Sanders, R.W.2
Lu, M.3
Klasse, P.J.4
Moore, J.P.5
-
49
-
-
34548434773
-
V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies
-
10.1371/journal.ppat.0030117, 1950945, 17722977
-
Laakso MM, Lee FH, Haggarty B, Agrawal C, Nolan KM, Biscone M, Romano J, Jordan AP, Leslie GJ, Meissner EG. V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies. PLoS Pathog 2007, 3(8):e117. 10.1371/journal.ppat.0030117, 1950945, 17722977.
-
(2007)
PLoS Pathog
, vol.3
, Issue.8
-
-
Laakso, M.M.1
Lee, F.H.2
Haggarty, B.3
Agrawal, C.4
Nolan, K.M.5
Biscone, M.6
Romano, J.7
Jordan, A.P.8
Leslie, G.J.9
Meissner, E.G.10
-
50
-
-
70450170953
-
Structure-function analysis of human immunodeficiency virus type 1 gp120 amino acid mutations associated with resistance to the CCR5 coreceptor antagonist vicriviroc
-
10.1128/JVI.01351-09, 2786753, 19776131
-
Ogert RA, Ba L, Hou Y, Buontempo C, Qiu P, Duca J, Murgolo N, Buontempo P, Ralston R, Howe JA. Structure-function analysis of human immunodeficiency virus type 1 gp120 amino acid mutations associated with resistance to the CCR5 coreceptor antagonist vicriviroc. J Virol 2009, 83(23):12151-12163. 10.1128/JVI.01351-09, 2786753, 19776131.
-
(2009)
J Virol
, vol.83
, Issue.23
, pp. 12151-12163
-
-
Ogert, R.A.1
Ba, L.2
Hou, Y.3
Buontempo, C.4
Qiu, P.5
Duca, J.6
Murgolo, N.7
Buontempo, P.8
Ralston, R.9
Howe, J.A.10
-
51
-
-
79955398621
-
HIV-1 escape from the CCR5 antagonist maraviroc associated with an altered and less efficient mechanism of gp120-CCR5 engagement that attenuates macrophage-tropism
-
10.1128/JVI.00106-11, 3126252, 21345957
-
Roche M, Jakobsen MR, Sterjovski J, Ellett A, Posta F, Lee B, Jubb B, Westby M, Lewin SR, Ramsland PA. HIV-1 escape from the CCR5 antagonist maraviroc associated with an altered and less efficient mechanism of gp120-CCR5 engagement that attenuates macrophage-tropism. J Virol 2011, 85:4330-4342. 10.1128/JVI.00106-11, 3126252, 21345957.
-
(2011)
J Virol
, vol.85
, pp. 4330-4342
-
-
Roche, M.1
Jakobsen, M.R.2
Sterjovski, J.3
Ellett, A.4
Posta, F.5
Lee, B.6
Jubb, B.7
Westby, M.8
Lewin, S.R.9
Ramsland, P.A.10
-
52
-
-
84877637186
-
Maraviroc-resistant viruses continue to use the extracellular loop and N-terminal regions of CCR5 for cell entry
-
Boston, February 27-March 2 Poster P590
-
Jubb B, Buttler S, Craig C, Westby M. Maraviroc-resistant viruses continue to use the extracellular loop and N-terminal regions of CCR5 for cell entry. Program and Abstracts of the 18th Conference on Retroviruses and Opportunistic Infections 2011, Boston, February 27-March 2 Poster P590.
-
(2011)
Program and Abstracts of the 18th Conference on Retroviruses and Opportunistic Infections
-
-
Jubb, B.1
Buttler, S.2
Craig, C.3
Westby, M.4
-
53
-
-
20644453529
-
Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D)
-
10.1016/j.virol.2005.04.035, 15935415
-
Marozsan AJ, Kuhmann SE, Morgan T, Herrera C, Rivera-Troche E, Xu S, Baroudy BM, Strizki J, Moore JP. Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D). Virology 2005, 338(1):182-199. 10.1016/j.virol.2005.04.035, 15935415.
-
(2005)
Virology
, vol.338
, Issue.1
, pp. 182-199
-
-
Marozsan, A.J.1
Kuhmann, S.E.2
Morgan, T.3
Herrera, C.4
Rivera-Troche, E.5
Xu, S.6
Baroudy, B.M.7
Strizki, J.8
Moore, J.P.9
-
54
-
-
0037039380
-
HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use
-
10.1073/pnas.012519099, 117571, 11782552
-
Trkola A, Kuhmann SE, Strizki JM, Maxwell E, Ketas T, Morgan T, Pugach P, Xu S, Wojcik L, Tagat J. HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proc Natl Acad Sci USA 2002, 99(1):395-400. 10.1073/pnas.012519099, 117571, 11782552.
-
(2002)
Proc Natl Acad Sci USA
, vol.99
, Issue.1
, pp. 395-400
-
-
Trkola, A.1
Kuhmann, S.E.2
Strizki, J.M.3
Maxwell, E.4
Ketas, T.5
Morgan, T.6
Pugach, P.7
Xu, S.8
Wojcik, L.9
Tagat, J.10
-
55
-
-
77952909975
-
Shift in phenotypic susceptibility suggests a competition mechanism in a case of acquired resistance to maraviroc
-
10.1097/QAD.0b013e328338b7a6, 20559045
-
Delobel P, Raymond S, Mavigner M, Cazabat M, Alvarez M, Marchou B, Massip P, Izopet J. Shift in phenotypic susceptibility suggests a competition mechanism in a case of acquired resistance to maraviroc. AIDS 2010, 24(9):1382-1384. 10.1097/QAD.0b013e328338b7a6, 20559045.
-
(2010)
AIDS
, vol.24
, Issue.9
, pp. 1382-1384
-
-
Delobel, P.1
Raymond, S.2
Mavigner, M.3
Cazabat, M.4
Alvarez, M.5
Marchou, B.6
Massip, P.7
Izopet, J.8
-
56
-
-
56549124268
-
Characterization of maraviroc resistance in patients failing treatment with CCR5-tropic virus in MOTIVATE 1 and MOTIVATE 2 (24 week analysis)
-
Mori J, Lewis M, Simpson P, Whitcomb J, Perros M, van der Ryst E, Westby M. Characterization of maraviroc resistance in patients failing treatment with CCR5-tropic virus in MOTIVATE 1 and MOTIVATE 2 (24 week analysis). Program and abstracts of the 6th European Drug Resistance Workshop, Budapest, March 26-28 Poster 51 2008,
-
(2008)
Program and abstracts of the 6th European Drug Resistance Workshop, Budapest, March 26-28 Poster 51
-
-
Mori, J.1
Lewis, M.2
Simpson, P.3
Whitcomb, J.4
Perros, M.5
van der Ryst, E.6
Westby, M.7
-
57
-
-
84878904611
-
The magnitude of HIV-1 resistance to the CCR5 antagonist maraviroc may impart a differential alteration in HIV-1 tropism for macrophages and T-cell subsets
-
Flynn JK, Paukovics G, Moore MS, Ellett A, Gray LR, Duncan R, Salimi H, Jubb B, Westby M, Purcell DFJ. The magnitude of HIV-1 resistance to the CCR5 antagonist maraviroc may impart a differential alteration in HIV-1 tropism for macrophages and T-cell subsets. Virology 2013,
-
(2013)
Virology
-
-
Flynn, J.K.1
Paukovics, G.2
Moore, M.S.3
Ellett, A.4
Gray, L.R.5
Duncan, R.6
Salimi, H.7
Jubb, B.8
Westby, M.9
Purcell, D.F.J.10
-
58
-
-
80355145632
-
HIV-1 predisposed to acquiring resistance to maraviroc (MVC) and other CCR5 antagonists in vitro has an inherent, low-level ability to utilize MVC-bound CCR5 for entry
-
10.1186/1742-4690-8-89, 3217884, 22054077
-
Roche M, Jakobsen MR, Ellett A, Salimiseyedabad H, Jubb B, Westby M, Lee B, Lewin SR, Churchill MJ, Gorry PR. HIV-1 predisposed to acquiring resistance to maraviroc (MVC) and other CCR5 antagonists in vitro has an inherent, low-level ability to utilize MVC-bound CCR5 for entry. Retrovirology 2011, 8(1):89. 10.1186/1742-4690-8-89, 3217884, 22054077.
-
(2011)
Retrovirology
, vol.8
, Issue.1
, pp. 89
-
-
Roche, M.1
Jakobsen, M.R.2
Ellett, A.3
Salimiseyedabad, H.4
Jubb, B.5
Westby, M.6
Lee, B.7
Lewin, S.R.8
Churchill, M.J.9
Gorry, P.R.10
-
59
-
-
70350316187
-
A quantitative affinity-profiling system that reveals distinct CD4/CCR5 usage patterns among human immunodeficiency virus type 1 and simian immunodeficiency virus strains
-
10.1128/JVI.01242-09, 2772777, 19692480
-
Johnston SH, Lobriz MA, Nguyen S, Lassen K, Delair S, Posta F, Bryson YJ, Arts EJ, Chou T, Lee B. A quantitative affinity-profiling system that reveals distinct CD4/CCR5 usage patterns among human immunodeficiency virus type 1 and simian immunodeficiency virus strains. J Virol 2009, 83:11016-11026. 10.1128/JVI.01242-09, 2772777, 19692480.
-
(2009)
J Virol
, vol.83
, pp. 11016-11026
-
-
Johnston, S.H.1
Lobriz, M.A.2
Nguyen, S.3
Lassen, K.4
Delair, S.5
Posta, F.6
Bryson, Y.J.7
Arts, E.J.8
Chou, T.9
Lee, B.10
-
60
-
-
84870700527
-
Affinofile profiling: How efficiency of CD4/CCR5 usage impacts the biological and pathogenic phenotype of HIV
-
10.1016/j.virol.2012.09.043, 23217618
-
Chikere K, Chou T, Gorry PR, Lee B. Affinofile profiling: How efficiency of CD4/CCR5 usage impacts the biological and pathogenic phenotype of HIV. Virology 2013, 435:81-91. 10.1016/j.virol.2012.09.043, 23217618.
-
(2013)
Virology
, vol.435
, pp. 81-91
-
-
Chikere, K.1
Chou, T.2
Gorry, P.R.3
Lee, B.4
-
61
-
-
38949160397
-
Asn 362 in gp120 contributes to enhanced fusogenicity by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with AIDS
-
10.1186/1742-4690-4-89, 2225424, 18076768
-
Sterjovski J, Churchill MJ, Ellett A, Gray LR, Roche MJ, Dunfee RL, Purcell DF, Saksena N, Wang B, Sonza S. Asn 362 in gp120 contributes to enhanced fusogenicity by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with AIDS. Retrovirology 2007, 4:89. 10.1186/1742-4690-4-89, 2225424, 18076768.
-
(2007)
Retrovirology
, vol.4
, pp. 89
-
-
Sterjovski, J.1
Churchill, M.J.2
Ellett, A.3
Gray, L.R.4
Roche, M.J.5
Dunfee, R.L.6
Purcell, D.F.7
Saksena, N.8
Wang, B.9
Sonza, S.10
-
62
-
-
77954532945
-
An altered and more efficient mechanism of CCR5 engagement contributes to macrophage tropism of CCR5-using HIV-1 envelopes
-
10.1016/j.virol.2010.05.006, 3096480, 20570309
-
Sterjovski J, Roche M, Churchill MJ, Ellett A, Farrugia W, Gray LR, Cowley D, Poumbourios P, Lee B, Wesselingh S. An altered and more efficient mechanism of CCR5 engagement contributes to macrophage tropism of CCR5-using HIV-1 envelopes. Virology 2010, 404:269-278. 10.1016/j.virol.2010.05.006, 3096480, 20570309.
-
(2010)
Virology
, vol.404
, pp. 269-278
-
-
Sterjovski, J.1
Roche, M.2
Churchill, M.J.3
Ellett, A.4
Farrugia, W.5
Gray, L.R.6
Cowley, D.7
Poumbourios, P.8
Lee, B.9
Wesselingh, S.10
-
63
-
-
84871974796
-
HIV-1 resistance to maraviroc conferred by a Cd4 binding site mutation in the envelope glycoprotein Gp120
-
Ratcliff AN, Shi W, Arts EJ. HIV-1 resistance to maraviroc conferred by a Cd4 binding site mutation in the envelope glycoprotein Gp120. J Virol 2012, 87:923-934.
-
(2012)
J Virol
, vol.87
, pp. 923-934
-
-
Ratcliff, A.N.1
Shi, W.2
Arts, E.J.3
-
64
-
-
80054967003
-
Alternative coreceptor requirements for efficient CCR5- and CXCR4-mediated HIV-1 entry into macrophages
-
10.1128/JVI.05510-11, 3187472, 21835796
-
Cashin K, Roche M, Sterjovski J, Ellett A, Gray LR, Cunningham AL, Ramsland PA, Churchill MJ, Gorry PR. Alternative coreceptor requirements for efficient CCR5- and CXCR4-mediated HIV-1 entry into macrophages. J Virol 2011, 85:10699-10709. 10.1128/JVI.05510-11, 3187472, 21835796.
-
(2011)
J Virol
, vol.85
, pp. 10699-10709
-
-
Cashin, K.1
Roche, M.2
Sterjovski, J.3
Ellett, A.4
Gray, L.R.5
Cunningham, A.L.6
Ramsland, P.A.7
Churchill, M.J.8
Gorry, P.R.9
-
65
-
-
84871976641
-
Macrophage-tropic HIV-1 variants from brain demonstrate alterations in the way gp120 engages both CD4 and CCR5
-
10.1189/jlb.0612308, 23077246
-
Salimi H, Roche M, Webb N, Gray LR, Chikere K, Sterjovski J, Ellett A, Wesselingh SL, Ramsland PA, Lee B. Macrophage-tropic HIV-1 variants from brain demonstrate alterations in the way gp120 engages both CD4 and CCR5. J Leukoc Biol 2013, 93:113-126. 10.1189/jlb.0612308, 23077246.
-
(2013)
J Leukoc Biol
, vol.93
, pp. 113-126
-
-
Salimi, H.1
Roche, M.2
Webb, N.3
Gray, L.R.4
Chikere, K.5
Sterjovski, J.6
Ellett, A.7
Wesselingh, S.L.8
Ramsland, P.A.9
Lee, B.10
-
66
-
-
0033994315
-
Envelope glycoprotein determinants of increased fusogenicity in a pathogenic simian-human immunodeficiency virus (SHIV-KB9) passaged in vivo
-
10.1128/JVI.74.9.4433-4440.2000, 111962, 10756060
-
Etemad-Moghadam B, Sun Y, Nicholson EK, Fernandes M, Liou K, Gomila R, Lee J, Sodroski J. Envelope glycoprotein determinants of increased fusogenicity in a pathogenic simian-human immunodeficiency virus (SHIV-KB9) passaged in vivo. J Virol 2000, 74(9):4433-4440. 10.1128/JVI.74.9.4433-4440.2000, 111962, 10756060.
-
(2000)
J Virol
, vol.74
, Issue.9
, pp. 4433-4440
-
-
Etemad-Moghadam, B.1
Sun, Y.2
Nicholson, E.K.3
Fernandes, M.4
Liou, K.5
Gomila, R.6
Lee, J.7
Sodroski, J.8
-
67
-
-
84869106867
-
Enhanced Recognition and Neutralization of HIV-1 by Antibody-Derived CCR5-Mimetic Peptide Variants
-
10.1128/JVI.00967-12, 3486504, 22933279
-
Chiang JJ, Gardner MR, Quinlan BD, Dorfman T, Choe H, Farzan M. Enhanced Recognition and Neutralization of HIV-1 by Antibody-Derived CCR5-Mimetic Peptide Variants. J Virol 2012, 86(22):12417-12421. 10.1128/JVI.00967-12, 3486504, 22933279.
-
(2012)
J Virol
, vol.86
, Issue.22
, pp. 12417-12421
-
-
Chiang, J.J.1
Gardner, M.R.2
Quinlan, B.D.3
Dorfman, T.4
Choe, H.5
Farzan, M.6
-
68
-
-
79960411519
-
A tyrosine-sulfated CCR5-mimetic peptide promotes conformational transitions in the HIV-1 envelope glycoprotein
-
10.1128/JVI.00630-11, 3147930, 21613393
-
Kwong JA, Dorfman T, Quinlan BD, Chiang JJ, Ahmed AA, Choe H, Farzan M. A tyrosine-sulfated CCR5-mimetic peptide promotes conformational transitions in the HIV-1 envelope glycoprotein. J Virol 2011, 85(15):7563-7571. 10.1128/JVI.00630-11, 3147930, 21613393.
-
(2011)
J Virol
, vol.85
, Issue.15
, pp. 7563-7571
-
-
Kwong, J.A.1
Dorfman, T.2
Quinlan, B.D.3
Chiang, J.J.4
Ahmed, A.A.5
Choe, H.6
Farzan, M.7
-
69
-
-
0037174994
-
Tyrosine-sulfated peptides functionally reconstitute a CCR5 variant lacking a critical amino-terminal region
-
10.1074/jbc.M206784200, 12183462
-
Farzan M, Chung S, Li W, Vasilieva N, Wright PL, Schnitzler CE, Marchione RJ, Gerard C, Gerard NP, Sodroski J. Tyrosine-sulfated peptides functionally reconstitute a CCR5 variant lacking a critical amino-terminal region. J Biol Chem 2002, 277(43):40397-40402. 10.1074/jbc.M206784200, 12183462.
-
(2002)
J Biol Chem
, vol.277
, Issue.43
, pp. 40397-40402
-
-
Farzan, M.1
Chung, S.2
Li, W.3
Vasilieva, N.4
Wright, P.L.5
Schnitzler, C.E.6
Marchione, R.J.7
Gerard, C.8
Gerard, N.P.9
Sodroski, J.10
-
70
-
-
79957718974
-
Divergent and site-selective solid-phase synthesis of sulfopeptides
-
10.1002/asia.201100232, 21509944
-
Taleski D, Butler SJ, Stone MJ, Payne RJ. Divergent and site-selective solid-phase synthesis of sulfopeptides. Chem Asian J 2011, 6:1316-1320. 10.1002/asia.201100232, 21509944.
-
(2011)
Chem Asian J
, vol.6
, pp. 1316-1320
-
-
Taleski, D.1
Butler, S.J.2
Stone, M.J.3
Payne, R.J.4
-
71
-
-
60549105011
-
Regulation of chemokine recognition by site-specific tyrosine sulfation of receptor peptides
-
10.1016/j.chembiol.2008.12.007, 2678197, 19246006
-
Simpson LS, Zhu JZ, Widlanski TS, Stone MJ. Regulation of chemokine recognition by site-specific tyrosine sulfation of receptor peptides. Chem Biol 2009, 16(2):153-161. 10.1016/j.chembiol.2008.12.007, 2678197, 19246006.
-
(2009)
Chem Biol
, vol.16
, Issue.2
, pp. 153-161
-
-
Simpson, L.S.1
Zhu, J.Z.2
Widlanski, T.S.3
Stone, M.J.4
-
72
-
-
79952131553
-
Tyrosine sulfation influences the chemokine binding selectivity of peptides derived from chemokine receptor CCR3
-
10.1021/bi101240v, 21235238
-
Zhu JZ, Millard CJ, Ludeman JP, Simpson LS, Clayton DJ, Payne RJ, Widlanski TS, Stone MJ. Tyrosine sulfation influences the chemokine binding selectivity of peptides derived from chemokine receptor CCR3. Biochemistry 2011, 50(9):1524-1534. 10.1021/bi101240v, 21235238.
-
(2011)
Biochemistry
, vol.50
, Issue.9
, pp. 1524-1534
-
-
Zhu, J.Z.1
Millard, C.J.2
Ludeman, J.P.3
Simpson, L.S.4
Clayton, D.J.5
Payne, R.J.6
Widlanski, T.S.7
Stone, M.J.8
-
73
-
-
34848868199
-
Structures of the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1 gp120 and CD4
-
10.1126/science.1145373, 2278242, 17901336
-
Huang CC, Lam SN, Acharya P, Tang M, Xiang SH, Hussan SS, Stanfield RL, Robinson J, Sodroski J, Wilson IA. Structures of the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1 gp120 and CD4. Science 2007, 317(5846):1930-1934. 10.1126/science.1145373, 2278242, 17901336.
-
(2007)
Science
, vol.317
, Issue.5846
, pp. 1930-1934
-
-
Huang, C.C.1
Lam, S.N.2
Acharya, P.3
Tang, M.4
Xiang, S.H.5
Hussan, S.S.6
Stanfield, R.L.7
Robinson, J.8
Sodroski, J.9
Wilson, I.A.10
-
74
-
-
84863393752
-
V3 determinants of HIV-1 escape from the CCR5 inhibitors Maraviroc and Vicriviroc
-
10.1016/j.virol.2012.02.006, 22424737
-
Berro R, Klasse PJ, Jakobsen MR, Gorry PR, Moore JP, Sanders RW. V3 determinants of HIV-1 escape from the CCR5 inhibitors Maraviroc and Vicriviroc. Virology 2012, 427(2):158-165. 10.1016/j.virol.2012.02.006, 22424737.
-
(2012)
Virology
, vol.427
, Issue.2
, pp. 158-165
-
-
Berro, R.1
Klasse, P.J.2
Jakobsen, M.R.3
Gorry, P.R.4
Moore, J.P.5
Sanders, R.W.6
-
75
-
-
0031954686
-
Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1
-
109730, 9525605
-
Platt EJ, Wehrly K, Kuhmann SE, Chesebro B, Kabat D. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol 1998, 72(4):2855-2864. 109730, 9525605.
-
(1998)
J Virol
, vol.72
, Issue.4
, pp. 2855-2864
-
-
Platt, E.J.1
Wehrly, K.2
Kuhmann, S.E.3
Chesebro, B.4
Kabat, D.5
-
76
-
-
0033542116
-
Establishment of a new system for determination of coreceptor usages of HIV based on the human glioma NP-2 cell line
-
10.1006/bbrc.1999.0633, 10329384
-
Soda Y, Shimizu N, Jinno A, Liu HY, Kanbe K, Kitamura T, Hoshino H. Establishment of a new system for determination of coreceptor usages of HIV based on the human glioma NP-2 cell line. Biochem Biophys Res Commun 1999, 258(2):313-321. 10.1006/bbrc.1999.0633, 10329384.
-
(1999)
Biochem Biophys Res Commun
, vol.258
, Issue.2
, pp. 313-321
-
-
Soda, Y.1
Shimizu, N.2
Jinno, A.3
Liu, H.Y.4
Kanbe, K.5
Kitamura, T.6
Hoshino, H.7
-
77
-
-
0030018993
-
Molecular cloning and analysis of functional envelope genes from human immunodeficiency virus type 1 sequence subtypes A through G
-
Gao F, Morrison SG, Robertson DL, Thornton CL, Craig S, Karlsson G, Sodroski J, Morgado M, Galvao-Castro B, von Briesen H. Molecular cloning and analysis of functional envelope genes from human immunodeficiency virus type 1 sequence subtypes A through G. The WHO and NIAID Networks for HIV Isolation and Characterization. J Virol 1996, 70(3):1651-1667.
-
(1996)
The WHO and NIAID Networks for HIV Isolation and Characterization. J Virol
, vol.70
, Issue.3
, pp. 1651-1667
-
-
Gao, F.1
Morrison, S.G.2
Robertson, D.L.3
Thornton, C.L.4
Craig, S.5
Karlsson, G.6
Sodroski, J.7
Morgado, M.8
Galvao-Castro, B.9
von Briesen, H.10
-
78
-
-
66149133705
-
Tissue-specific sequence alterations in the human immunodeficiency virus type 1 envelope favoring CCR5 usage contribute to persistence of dual-tropic virus in the brain
-
10.1128/JVI.02648-08, 2681927, 19321618
-
Gray L, Roche M, Churchill MJ, Sterjovski J, Ellett A, Poumbourios P, Sherieff S, Wang B, Saksena N, Purcell DF. Tissue-specific sequence alterations in the human immunodeficiency virus type 1 envelope favoring CCR5 usage contribute to persistence of dual-tropic virus in the brain. J Virol 2009, 83(11):5430-5441. 10.1128/JVI.02648-08, 2681927, 19321618.
-
(2009)
J Virol
, vol.83
, Issue.11
, pp. 5430-5441
-
-
Gray, L.1
Roche, M.2
Churchill, M.J.3
Sterjovski, J.4
Ellett, A.5
Poumbourios, P.6
Sherieff, S.7
Wang, B.8
Saksena, N.9
Purcell, D.F.10
-
79
-
-
0030018993
-
Molecular cloning and analysis of functional envelope genes from human immunodeficiency virus type 1 sequence subtypes A through G. The WHO and NIAID Networks for HIV Isolation and Characterization
-
189989, 8627686
-
Gao F, Morrison SG, Robertson DL, Thornton CL, Craig S, Karlsson G, Sodroski J, Morgado M, Galvao-Castro B, von Briesen H. Molecular cloning and analysis of functional envelope genes from human immunodeficiency virus type 1 sequence subtypes A through G. The WHO and NIAID Networks for HIV Isolation and Characterization. J Virol 1996, 70(3):1651-1667. 189989, 8627686.
-
(1996)
J Virol
, vol.70
, Issue.3
, pp. 1651-1667
-
-
Gao, F.1
Morrison, S.G.2
Robertson, D.L.3
Thornton, C.L.4
Craig, S.5
Karlsson, G.6
Sodroski, J.7
Morgado, M.8
Galvao-Castro, B.9
von Briesen, H.10
-
80
-
-
0035155850
-
Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers
-
10.1128/JVI.75.3.1165-1171.2001, 114022, 11152489
-
Yang X, Wyatt R, Sodroski J. Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers. J Virol 2001, 75(3):1165-1171. 10.1128/JVI.75.3.1165-1171.2001, 114022, 11152489.
-
(2001)
J Virol
, vol.75
, Issue.3
, pp. 1165-1171
-
-
Yang, X.1
Wyatt, R.2
Sodroski, J.3
-
81
-
-
0033609149
-
Quantification of CD4, CCR5, and CXCR4 levels on lymphocyte subsets, dendritic cells, and differentially conditioned monocyte-derived macrophages
-
10.1073/pnas.96.9.5215, 21844, 10220446
-
Lee B, Sharron M, Montaner LJ, Weissman D, Doms RW. Quantification of CD4, CCR5, and CXCR4 levels on lymphocyte subsets, dendritic cells, and differentially conditioned monocyte-derived macrophages. Proc Natl Acad Sci USA 1999, 96(9):5215-5220. 10.1073/pnas.96.9.5215, 21844, 10220446.
-
(1999)
Proc Natl Acad Sci USA
, vol.96
, Issue.9
, pp. 5215-5220
-
-
Lee, B.1
Sharron, M.2
Montaner, L.J.3
Weissman, D.4
Doms, R.W.5
-
82
-
-
78751705594
-
CD4-binding site alterations in CCR5-using HIV-1 envelopes influencing gp120-CD4 interactions and fusogenicity
-
10.1016/j.virol.2010.12.010, 21216423
-
Sterjovski J, Churchill MJ, Roche M, Ellett A, Farrugia W, Wesselingh SL, Cunningham AL, Ramsland PA, Gorry PR. CD4-binding site alterations in CCR5-using HIV-1 envelopes influencing gp120-CD4 interactions and fusogenicity. Virology 2011, 410:418-428. 10.1016/j.virol.2010.12.010, 21216423.
-
(2011)
Virology
, vol.410
, pp. 418-428
-
-
Sterjovski, J.1
Churchill, M.J.2
Roche, M.3
Ellett, A.4
Farrugia, W.5
Wesselingh, S.L.6
Cunningham, A.L.7
Ramsland, P.A.8
Gorry, P.R.9
-
83
-
-
0027136282
-
Comparative protein modelling by satisfaction of spatial restraints
-
10.1006/jmbi.1993.1626, 8254673
-
Sali A, Blundell TL. Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol 1993, 234(3):779-815. 10.1006/jmbi.1993.1626, 8254673.
-
(1993)
J Mol Biol
, vol.234
, Issue.3
, pp. 779-815
-
-
Sali, A.1
Blundell, T.L.2
|